先天性心脏病患者中的皮下植入式心律转复除颤器
这项法国全国性队列研究分析了101例先天性心脏病(CHD)患者使用皮下植入式心律转复除颤器(S-ICD)的结果。CHD患者占所有S-ICD植入者的2.1%,平均随访1.9年,15.8%接受至少一次恰当电击且均成功终止室性心律失常。倾向匹配后,CHD与非CHD患者的恰当电击风险无显著差异,并发症和不当电击负担相当。
要点
- CHD患者占S-ICD植入者的2.1%,以法洛四联症、单心室和右型大动脉转位为主。
- CHD患者平均随访1.9年,15.8%接受恰当电击且均成功终止室性心律失常。
- 倾向匹配后CHD与非CHD患者的恰当电击、并发症及不当电击风险均无显著差异。
核心结论
- S-ICD在CHD这一高危人群中有效且安全,恰当电击均成功终止室性心律失常,并发症和不当电击负担与非CHD患者相当。
研究设计与样本
- 法国全国性队列研究(HONEST,NCT05302115),纳入2012年10月12日至2019年12月31日在150个中心植入S-ICD的全部4924例患者,其中101例(2.1%)为CHD。
主要发现
- CHD患者年龄37.1±15.4岁,非CHD患者50.1±14.9岁(P<0.001)。
- CHD患者女性占37.6%,非CHD患者占23.0%(P<0.001)。
- CHD患者因二级预防植入S-ICD占72.3%,非CHD患者占35.9%(P<0.001)。
- CHD患者合并体循环心室严重收缩功能不全占28.1%,非CHD患者占53.1%(P<0.001)。
- CHD患者恰当电击年发生率为9.0%,非CHD患者为4.4%(HR:2.1;95%CI:1.3-3.4);倾向匹配后该关联不再显著(P=0.12)。
关键数值与推荐
- CHD患者恰当电击年发生率9.0%,非CHD患者4.4%(HR:2.1;95%CI:1.3-3.4)。
- CHD患者全因并发症HR:1.2(95%CI:0.7-2.1;P=0.4),不当电击HR:0.9(95%CI:0.4-2.0;P=0.9)。
- CHD患者平均随访1.9年,16例(15.8%)接受至少一次恰当电击,均成功终止室性心律失常。
临床怎么用
- 对于符合适应证的CHD患者,S-ICD可作为预防心源性猝死的有效且安全选择。
- CHD患者植入S-ICD后恰当电击风险较高,但倾向匹配后与非CHD患者无显著差异。
- CHD患者使用S-ICD的并发症和不当电击风险与非CHD患者相当,支持其在这一高危人群中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Very few data have been published on the use of subcutaneous implantable cardioverter-defibrillators (S-ICDs) in patients with congenital heart disease (CHD). OBJECTIVES: The aim of this study was to analyze outcomes associated with S-ICDs in patients with CHD. METHODS: This nationwide French cohort including all patients with an S-ICD was initiated in 2020 by the French Institute of Health and Medical Research. Characteristics at implantation and outcomes were analyzed in patients with CHD. RESULTS: From October 12, 2012, to December 31, 2019, among 4,924 patients receiving an S-ICD implant in 150 centers, 101 (2.1%) had CHD. Tetralogy of Fallot, univentricular heart, and dextro-transposition of the great arteries represented almost one-half of the population. Patients with CHD were significantly younger (age 37.1 ± 15.4 years vs 50.1 ± 14.9 years; P < 0.001), more frequently female (37.6% vs 23.0%; P < 0.001), more likely to receive an S-ICD for secondary prevention (72.3% vs 35.9%; P < 0.001), and less likely to have severe systolic dysfunction of the systemic ventricle (28.1% vs 53.1%; P < 0.001). Over a mean follow-up period of 1.9 years, 16 (15.8%) patients with CHD received at least 1 appropriate shock, with all shocks successfully terminating the ventricular arrhythmia. The crude risk of appropriate S-ICD shock was twice as high in patients with CHD compared with non-CHD patients (annual incidences of 9.0% vs 4.4%; HR: 2.1; 95% CI: 1.3-3.4); however, this association was no longer significant after propensity matching (especially considering S-ICD indication, P = 0.12). The burden of all complications (HR: 1.2; 95% CI: 0.7-2.1; P = 0.4) and inappropriate shocks (HR: 0.9; 95% CI: 0.4-2.0; P = 0.9) was comparable in both groups. CONCLUSIONS: In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115).
引用
- Waldmann V, Marquié C, Bessière F, et al. Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease. J Am Coll Cardiol. 2023. PMID: 37558371. doi:10.1016/j.jacc.2023.05.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。